Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 11/2013

01-11-2013 | EDUCATIONAL SERIES–RED SERIES

Zoledronic acid in genitourinary cancer

Authors: M. A. Climent, U. Anido, M. J. Méndez-Vidal, J. Puente

Published in: Clinical and Translational Oncology | Issue 11/2013

Login to get access

Abstract

Bone metastases are a common complication of advanced prostate cancer and while they are less common in non-prostate genitourinary (GU) malignances, they have been reported in up to 35 % of patients with advanced renal cell carcinoma and bladder cancer. Furthermore, they may occur in more than two-thirds of those patients with bladder cancer who develop distant metastases. In the absence of bone-targeted therapies, approximately 50 % of all patients with metastatic bone disease from GU cancers experience at least one skeletal-related event within their lifetime. Zoledronic acid is a bisphosphonate that has been shown to delay or prevent the development of skeletal complications in patients with bone metastases and reduce bone pain in these patients. Furthermore, zoledronic acid has also demonstrated the ability to prevent osteopenia, which may occur with the prolonged use of some pharmacological interventions in patients with cancer.
Literature
1.
Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165–76.PubMedCrossRef
2.
Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol. 2010;15:382–9.PubMedCrossRef
3.
4.
Bishr M, Saad F. Preventing bone complications in prostate cancer. Curr Opin Support Palliat Care. 2012;6(3):299–303.PubMedCrossRef
5.
Kurata T, Nakagawa K. Efficacy and safety of denosumab for the treatment of bone metastases in patients with advanced cancer. Jpn J Clin Oncol. 2012;42(8):663–9.PubMedCrossRef
6.
Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765–81.PubMedCrossRef
7.
8.
9.
Zekri J, Ahmed N, Coleman RE, Hancock BW. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol. 2001;19:379–82.PubMed
10.
Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003;98:962–9.PubMedCrossRef
11.
Riechelmann RP, Chin S, Wang L, Tannock IF, Berthold DR, Moore MJ, et al. Sorafenib for metastatic renal cancer: the Princess Margaret experience. Am J Clin Oncol. 2008;31:182–7.PubMedCrossRef
12.
Patil S, Figlin RA, Hutson TE, Michaelson MD, Négrier S, Kim ST, et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2011;22:295–300.PubMedCrossRef
13.
Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004;100(12):2613–21.PubMedCrossRef
14.
Agrillo A, Nastro Siniscalchi E, Facchini A, Filiaci F, Ungari C. Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports. Eur Rev Med Pharmacol Sci. 2012;16(7):952–7.PubMed
15.
Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, et al. Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer. 2012;107(10):1665–71.PubMedCrossRef
16.
Bozas G, Roy A, Ramasamy V, Maraveyas A. Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib. Onkologie. 2010;33(6):321–3.PubMedCrossRef
17.
Hoefert S, Eufinger H. Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110(4):463–9.PubMedCrossRef
18.
Keizman D, Ish-Shalom M, Pili R, Hammers H, Eisenberger MA, Sinibaldi V, et al. Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma. Eur J Cancer. 2012;48(7):1031–7.PubMedCrossRef
19.
MuIlin EM, Glenn JF, Paulson OF. Lesions of bone and bladder cancer. J Urol. 1975;13:45–6.
20.
Wirtanen GW, Miller AC. Bladder lymphatics and tumor dissemination. J Urol. 1973;9:58–9.
21.
Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial–the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol: Off J Am Soc Clin Oncol. 2003;21:3150–7.CrossRef
22.
Mulders PF, Abrahamsson PA, Bukowski RM. Burden of metastatic bone disease from genitourinary malignancies. Expert Rev Anticancer Ther. 2010;10:1721–33.PubMedCrossRef
23.
24.
Morrissey C, Vessella RL. The role of tumor microenvironment in prostate cancer bone metastasis. J Cell Biochem. 2007;101:873–86.PubMedCrossRef
25.
Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007;110:1860–7.PubMedCrossRef
26.
DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer. 2007;15:869–76.PubMedCrossRef
27.
28.
Cook RJ, Coleman R, Brown J, Lipton A, Major P, Hei YJ, et al. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer. Clin Cancer Res. 2006;12:3361–7.PubMedCrossRef
29.
30.
Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458–68.PubMedCrossRef
31.
Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879–82.PubMedCrossRef
32.
33.
Saylor PJ, Smith MR. Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol. 2009;181:1998–2008.PubMedCrossRef
34.
Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154–64.PubMedCrossRef
35.
Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J. Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol. 2006;175:136–9.PubMedCrossRef
36.
Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol. 2003;169:2008–12.PubMedCrossRef
37.
Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007;25:1038–42.PubMedCrossRef
38.
Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer. J Urol. 2006;176:972–8.PubMedCrossRef
39.
NCCN National Comprehensive Cancer Network. Clinical practice guidelines in oncology: prostate cancer, version 4. http://​www.​nccn.​org (2011). Accessed 3 Sept 2011.
40.
Mason MD, Sydes MR, Glaholm J, Langley RE, Huddart RA, Sokal M, et al. Oral sodium clodronate for non metastatic prostate cancer—results of a randomized double-blind placebo-controlled trial: medical research council PR04 (ISRCTN61384873). J Natl Cancer Inst. 2007;99:765–76.PubMedCrossRef
41.
Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005;23:2918–25.PubMedCrossRef
42.
Wirth M, Tammela T, DeBruyne F, Tubaro A, Witjes W, Patel A, et al (2008). Effectiveness of zoledronic acid for the prevention of bone metastases in high-risk prostate cancer patients: a randomised, open label, multicenter study of the European association of urology (EAU) in cooperation with the Scandinavian prostate cancer group (SPCG) and the arbeitsgemeinschaft urologische onkologie (AUO). A report of the ZEUS study. Program and abstracts of the 2008 American society of clinical oncology genitourinary cancers symposium; February 14–16 2008; San Francisco, California. abstract 184.
43.
Brown JE, Cook RJ, Major P, Lipton A, Saad F, Smith M, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005;97:59–69.PubMedCrossRef
44.
Lein M, Wirth M, Miller K, Eickenberg HU, Weissbach L, Schmidt K, et al. Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic acid for detection of bone metastases progression. Eur Urol. 2007;52:1381–7.PubMedCrossRef
45.
Izumi K, Mizokami A, Itai S, Shima T, Shigehara K, Miwa S, et al. Increases in bone turnover marker levels at an early phase after starting zoledronic acid predicts skeletal-related events in patients with prostate cancer with bone metastasis. BJU Int. 2012;109:394–400.PubMedCrossRef
46.
Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, et al. Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg. 2009;67:159–61.PubMedCrossRef
47.
Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, et al. Normal serum bone markers in bisphosphonate-induced osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;106:389–91.PubMedCrossRef
48.
Marini F, Tonelli P, Cavalli L, Cavalli T, Masi L, Falchetti A, et al. Pharmacogenetics of bisphosphonate-associated osteonecrosis of the jaw. Front Biosci (Elite Ed). 2011;3:364–70.CrossRef
49.
Marx RE, Joseph E, Cillo JE, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg. 2007;65:2397–410.PubMedCrossRef
50.
American Dental Association Council on Scientific Affairs. Expert panel recommendations: dental management of patients receiving oral bisphosphonate therapy. J Am Dental Assoc. 2006;137:1144–50.
51.
American Association of Oral and Maxillofacial Surgeons. Advisory task force on bisphosphonate-related osteonecrosis of the jaws, American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg. 2007;65:369–76.CrossRef
52.
Dunstan CR, Felsenberg D, Seibel MJ. Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol. 2007;4:42–55.PubMedCrossRef
53.
Chang JT, Green L, Beitz J, Tarassoff P, Hei YJ, Maladorno D. Renal failure with the use of zoledronic acid. N England J Med. 2003;349:1676–9.CrossRef
54.
Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol. 2006;7:508–14.PubMedCrossRef
55.
Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol. 2009;27:5356–62.PubMedCrossRef
56.
Antonini F, Pereira CC, Parente EV, Azambuja FG. Management of osteonecrosis of the jaws in patients with history of bisphosphonates therapy. J Craniofac Surg. 2010;21:1962–6.PubMedCrossRef
57.
Seth R, Futran ND, Alam DS, Knott PD. Outcomes of vascularized bone graft reconstruction of the mandible in bisphosphonate-related osteonecrosis of the jaws. Laryngoscope. 2010;120:2165–71.PubMedCrossRef
58.
Epstein MS, Wicknick FW, Epstein JB, Berenson JR, Gorsky M. Management of bisphosphonate-associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. an initial case series. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110:593–6.PubMedCrossRef
59.
Tirelli G, Biasotto M, Chiandussi S, Dore F, De Nardi E, Di Lenarda R. Bisphosphonate-associated osteonecrosis of the jaws: the limits of a conservative approach. Head Neck. 2009;31:1249–54.PubMedCrossRef
60.
Kademani D, Koka S, Lacy MQ, Rajkumar SV. Primary surgical therapy for osteonecrosis of the jaw secondary to bisphosphonate therapy. Mayo Clin Proc. 2006;81:1100–3.PubMedCrossRef
61.
Fraunfelder FW, Fraunfelder FT. Bisphosphonates and ocular inflammation. N Engl J Med. 2003;348:1187–8.PubMedCrossRef
62.
Papapetrou PD. Bisphosphonate-associated adverse events. Hormones. 2009;8:96–110.PubMed
63.
Benderson D, Karakunnel J, Kathuria S, Badros A. Scleritis complicating zoledronic acid infusion. Clin Lymphoma Myeloma. 2006;7:145–7.PubMedCrossRef
64.
El Saghir NS, Otrock ZK, Bleik JH. Unilateral uveitis complicating zoledronic acid therapy in breast cancer. BMC Cancer. 2005;5:156.PubMedCrossRef
65.
Kilickap S, Ozdamar Y, Altundag MK, Dizdar O. A case report: zoledronic acid-induced uveitis. Med Oncol. 2008;25:238–40.PubMedCrossRef
66.
Wilkinson GS, Baillargeon J, Kuo YF, Freeman JL, Goodwin JS. Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer. J Clin Oncol. 2010;28:4898–905.PubMedCrossRef
67.
Strang P, Nilsson S, Brändstedt S, Sehlin J, Borghede G, Varenhorst E, et al. The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer. Anticancer Res. 1997;17:4717–21.PubMed
68.
Smith JA. Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study. J Urol. 1989;141:85–7.PubMed
69.
Wiktor-Jedrzejczak W. Reduction of pain as the primary determinant of improved quality of life of cancer patients receiving zoledronic acid (zol) for bone involvement. ASCO Meeting Abstracts. 2005;23:8022.
70.
Al Farhat YB, Cseh J, Boer K, Csepreghy M, Pajor L, Thurzo L, et al. A multicenter, open-label study to determine the effect of intravenous zoledronic acid (ZOL) on pain and quality of life in patients with bone metastases with or without skeletal-related events (SREs) resulting from breast cancer (BC) and prostate cancer (PC). ASCO Meeting Abstracts. 2011;29:e19558.
71.
Costa L, Major PP. Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol. 2009;6:163–74.PubMedCrossRef
72.
73.
Bouganim N, Dranitsaris G, Amir E, Clemons M. Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists. Support Care Cancer. 2011;19(11):1687–96.PubMedCrossRef
74.
Spencer S, Marini BL, Figg WD. Novel approaches in the pharmacotherapy of skeletal-related events in metastatic castrate-resistant prostate cancer. Anticancer Res. 2012;32(7):2391–8.PubMed
Metadata
Title
Zoledronic acid in genitourinary cancer
Authors
M. A. Climent
U. Anido
M. J. Méndez-Vidal
J. Puente
Publication date
01-11-2013
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 11/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1033-1

Other articles of this Issue 11/2013

Clinical and Translational Oncology 11/2013 Go to the issue

Research Article

Gene diagnosis of micrometastases in regional lymph nodes of patients with stage I non-small cell lung cancer: impact on staging and prognosis

Research Article

Predictive and prognostic value of LPS-stimulated cytokine secretion in metastatic non-small cell lung cancer

Research Article

Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers?

Research Article

The application of ultrasonic harmonic scalpel in the radical surgery of gastric cancer

Educational Series – BLUE SERIES

Has discovery-based cancer research been a bust?

Research Article

Prognostic significance of annexin II expression in non-small cell lung cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits